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Atopic dermatitis (AD) is a pruritic recurring inflammatory skin disease. Recently, topical
tacrolimus has been developed to treat AD. This report presents the first clinical experience
with topical tacrolimus in Taiwan. This open-label, single-arm study was conducted at three
centers from February to May 2002. The duration of each individual treatment was 4 weeks.
Two groups were defined: pediatric and adult. Efficacy was evaluated on the basis of the
physician’s global evaluation at the end of treatment. Success was defined as at least 50%
improvement. Other evaluations included the Eczema Area and Severity Index (EASI), the
percentage of body surface area (BSA) involved, the patient’s assessment of pruritus, and
the patient’s assessment of overall response. Safety profile was established by monitoring
changes in hematology and biochemistry profiles and tacrolimus concentration in blood. All
adverse events were recorded. Twenty-six pediatric patients and 42 adult patients were
enrolled. Overall success rates were 80.8% and 82.1% in the pediatric and adult groups,
respectively. The declines in EASI, percentage of BSA affected, and patient’s assessment of
pruritus were significant (p < 0.001); 88% and 100% of pediatric and adult patients,
respectively, reported a favorable response to treatment. Changes in blood samples were
unremarkable. Of pediatric and adult patients, 61.5% and 76.2%, respectively, reported
adverse events. The most common adverse event reported was skin burning, which did not
result in discontinuation of therapy. This report reveals that tacrolimus ointment is effective
and safe for the treatment of AD in Taiwanese patients.
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Atopic dermatitis (AD) is a pruritic, recurring inflam-
matory skin disease that can have a negative impact
on patients’ health and quality of life [1–3]. It usually
develops in early childhood and is frequently seen in
children with a history of respiratory allergy and/or a
family history of atopic disease [1,4]. The prevalence
of AD has increased in recent years and, currently,
about 20% of the general population is affected by this
chronic skin condition [5,6]. The general therapeutic
approach for AD is directed at reducing inflammation
and improving symptoms such as intractable pruritus
and sleep disturbance. Depending on its severity, AD
is  most ly  managed with emoll ients ,  topical
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corticosteroids, antihistamines, and antibiotics [7–9].
For acute flares and refractory cases, systemic agents
such as corticosteroids and cyclosporine are some-
times used. However, a subgroup of patients, such as
those with long-standing disease or those with exten-
sive facial and body surface involvement, is difficult
to manage and poses a clinical challenge because of
their poor response to topical steroids and safety con-
cerns with long-term use of systemic agents.
Topical immunomodulators such as tacrolimus
ointment represent a new therapeutic option for these
patients. The mechanism of action of tacrolimus is
based on calcineurin inhibition, which results in the
suppression of antigen-presenting T cells and inhibi-
tion of inflammatory cytokine release [10,11].
Tacrolimus ointment has been used to treat AD in
children and adults in Europe, the USA, and Japan.
According to published results, tacrolimus ointment
is an effective therapeutic agent for AD with an accept-
able safety profile [12–16]. Recently, tacrolimus oint-
ment became available in Taiwan. This report presents
the efficacy results and safety profiles from the first
clinical experience with topical tacrolimus ointment
in Taiwanese patients with AD.
MATERIALS AND METHODS
This open-label, single-arm study was conducted at
three centers (Kaohsiung Medical University Chung-
Ho Memorial Hospital, National Taiwan University
Hospital, and Shin Kong Wu Ho-Su Memorial Hospital)
in Taiwan between February and May 2002. Patients
who met entry criteria were given 0.03% or 0.1%
tacrolimus ointment according to their age or the
investigator’s instruction. Those aged 2 to 15 years
were in the pediatric group and received 0.03%
tacrolimus ointment. Patients aged 16 years or older
were assigned to the adult group and received either
0.03% or 0.1% tacrolimus ointment. Treatment was
applied twice daily for 4 weeks to skin areas affected
by AD. Study protocols were identical at each center,
and patients gave written informed consent prior to
enrollment.
Patient selection
Male and female patients with a diagnosis of AD,
based on Hanifin and Rajka criteria [1], presenting
with  moderate to severe clinical manifestation, based
on Rajka and Langeland criteria [17], were enrolled in
the study. Minimum body surface area (BSA) involve-
ment was 10%, and patients were at least 2 years old.
Certain medication restrictions were imposed on
subjects. Prior to the study period, the use of astemizole
was prohibited for at least 6 weeks. In addition, non-
steroidal immunosuppressants (i.e. cyclosporine),
phototherapy,  systemic  s teroids ,  and other
investigational drugs were stopped for at least 4 weeks
before application of tacrolimus. Intranasal and/or
inhaled steroids were discontinued for at least 2 weeks
before tacrolimus therapy, and other non-sedating
antihistamines were not taken systemically for at least
1 week before. In addition, topical medications, in-
c l u d i n g  c o r t i c o s t e r o i d s  a n d  a n t i h i s t a m i n e
preparations, were prohibited for at least 1 week before.
As the trial began, all of these medications were
prohibited. Sedating antihistamines, such as diphen-
hydramine and chlorpheniramine, could be used dur-
ing the study period if patients were on a stable dose
at baseline and remained on that dose during the
study. The dosage of these medications could be de-
creased or discontinued, but not increased, during the
study period.
Treatment plan/evaluation
A thin layer of tacrolimus ointment was applied twice
daily to areas of active disease for 4 weeks. Patients
were evaluated weekly. Efficacy was evaluated based
on the physician’s global evaluation of clinical re-
sponse at the end of the trial. Success was defined as a
rating of better than moderate improvement (≥ 50%
improvement). Other evaluations included the Ec-
zema Area and Severity Index (EASI) [18], the percent-
age of BSA affected, the patient’s assessment of
pruritus, and the patient’s assessment of overall
response.
Calculation of the EASI score has been described
previously by Cherill et al [18]. Briefly, a standard
severity grading scale (0 = absent, 1 = mild, 2 =
moderate, 3 = severe) was used to rate the clinical
manifestations of AD. To calculate EASI, the grades
for certain clinical signs of AD were totaled (erythema
grade + edema/induration/papulation grade + exco-
riation grade + lichenification grade = total grade).
This total grade (TG) was multiplied by a converted
affected area score (AS). The AS was determined by
taking the physician’s assessment of the percentage of
BSA affected by AD in each region and converting it to
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a score based on a 7-point scale as follows: 0 = 0%, 1 =
1–9%, 2 = 10–29%, 3 = 30–49%, 4 = 50–69%, 5 = 70–89%,
and 6 = 90–100% affected area.
The total EASI score was calculated from the fol-
lowing equation: EASI = ([head/neck TG x AS] x
0.1) + ([upper limbs TG x AS] x 0.2) + ([trunk TG x AS]
x 0.3) + (lower limbs TG x AS) x 0.4. The highest
possible EASI score was 72.
The patient’s assessment of pruritus was done by
means of a 10 cm visual analog scale (0 cm = no itch, 10
cm = worst itch imaginable). The patient’s assessment
of overall response was categorized into seven stages,
from much better to much worse. For patients who
were too young to answer specific questions, the par-
ents’ or caregivers’ opinions were used for assessment.
To establish a safety profile, blood samples were
collected at the baseline visit, week 1, and week 4 to
document hematology and chemistry profiles and
tacrolimus concentrations. Blood tacrolimus concen-
trations were measured using a validated enzyme-
linked immunosorbent assay (ELISA), with a lower
limit of quantitation of 1.5 ng/mL. Patients were given
a journal to record any discomfort during the study
period. Safety was assessed from the incidence of
adverse events and changes from baseline in clinical
laboratory values.
Statistical analysis
All patients who received at least one application of
the study drug were included in the data analysis.
Demographics, disease information, and physician’s
global evaluation of clinical response for all enrolled
patients were tabulated. The paired t-test was used to
evaluate efficacy. Statistical tests were two-sided, and
a p value of less than 0.05 was considered statistically
significant. In order to be included in the efficacy
analysis, patients had to have received the study drug
for at least three consecutive days with a minimum of
five applications and not have violated the study
protocol. The safety parameters were tabulated for
analysis. All adverse events were documented, re-
gardless of relationship to the study drug. Laboratory
data were tabulated and summarized over time.
Changes from baseline for each hematologic and chemi-
cal variable were determined.
RESULTS
Demographics and baseline characteristics
A total of 68 patients were enrolled in three separate
centers, 26 in the pediatric group and 42 in the adult
group. Demographic and disease information are
shown in Table 1. Most patients presented with severe
clinical manifestation. Only 65 patients were included
in the efficacy analysis; three patients violated the
study protocol by taking unknown oral medications
during the study period. All 68 patients were included
in the safety evaluation.
Treatment efficacy
Physician’s global evaluation of clinical response
showed that AD responded favorably to topical
tacrolimus. Treatment was successful in 80.8% of the
pediatric group and 82.1% of the adult group (Table
2). Success rates were 69.2% and 74.4% in the pediatric
and adult groups, respectively, after only 1 week of
treatment.
Table 1. Demographic and disease information
Pediatric (n = 26) Adult (n = 42)
Age, yr (range) 8.5 ± 3.2 (4–15) 23.7 ± 8.3 (16–50)
Gender
Male 17 (65.4%) 30 (71.4%)
Female 9 (34.6%) 12 (28.6%)
Disease severity
Moderate 7 (26.9%) 12 (28.6%)
Severe 19 (73.1%) 30 (71.4%)
% BSA affected (range) 56.0 ± 28.0 (11.0–100) 62.9 ± 29.7 (13.5–100)
Demographic data, mean ± standard deviation. Disease severity was assigned according to the Rajka and Langeland criteria [17]. BSA = body
surface area.
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Other efficacy variables also showed a favorable
response. Initial EASIs in the pediatric and adult groups
were 32.5 ± 18.2 and 37.5 ± 20.2, respectively. By the
end of Week 4, the values had declined to 13.6 ± 11.7
and 18.9 ± 16.8, respectively (p < 0.001) (Figure 1). The
percentage BSA affected declined from 56.0 ± 28.0 to
29.7 ± 19.2% in the pediatric group and from 61.3 ±
20.2 to 40.5 ± 25.5% in the adult group by the end of the
treatment period (p < 0.001) (Figure 2).
Both pediatric and adult groups reported a statisti-
cally significant decline in pruritus, as determined by
visual analog scale (Figure 3). At baseline, the pediatric
and adult groups showed an itch score of 7.0 ± 2.2 and
7.2 ± 2.0, respectively. After 4 weeks of treatment, the
itch score had declined to 4.3 ± 3.0 and 3.8 ± 2.8,
respectively. As shown in Table 3, 88.5% of the pediatric
population and 100% of the adult patients reported a
favorable overall response. Figures 4 and 5 show im-
provements in selected lesions.
Safety profile
There were no remarkable changes in the hematology
and biochemistry profiles of any patient at the end of
the study period. Tacrolimus blood concentrations
were below the limit of quantitation (< 1.15 ng/mL) in
samples collected at all evaluated time points. Of
pediatric and adult patients, 61.5% and 76.2%,
respectively, reported adverse events. The most com-
Table 2. Physician’s global evaluation of clinical response by the end of the treatment period
Physician evaluation Pediatric (n = 26) Adult (n = 39)
Cleared 0 0
Excellent improvement 4 (15.4%) 4 (10.3%)
Marked improvement 6 (23.1%) 16 (41.0%)
Moderate improvement 11 (42.3%) 12 (30.8%)
Response* 21 (80.8%) 32 (82.1%)
Slight improvement 5 (19.2%) 7 (17.9%)
No appreciable improvement 0 0
Worse 0 0
*Response is defined as a rating of better than moderate (≥ 50%) improvement.
Figure 1. Change in Eczema Area and Severity Index (EASI) mean score during the study period. Differences between baseline and
Weeks 1, 2, 3 and 4, respectively, were statistically significant in each individual case (p < 0.001). SD = standard deviation.
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Table 3. Patient’s assessment of overall response
Response Pediatric (n = 26) Adult (n = 39)
Much better 5 (19.2%) 8 (20.5%)
Better 10 (38.5%) 13 (33.3%)
Slightly better 8 (30.8%) 18 (46.2%)
Same 1 (3.8%) 0
Slightly worse 2 (7.7%) 0
Worse 0 0
Much worse 0 0
Figure 2. Mean change in percentage of body surface area (BSA) affected during the course of treatment. Differences between baseline
and Weeks 1, 2, 3 and 4, respectively, were statistically significant in each individual case (p < 0.001). SD = standard deviation.
Figure 3. Changes in mean patient pruritus score during the course of treatment. Differences between baseline and Weeks 1, 2, 3 and
4, respectively, were statistically significant in each individual case (p < 0.001). SD = standard deviation.
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mon adverse event reported in both pediatric and adult
patients was skin burning, with incidences of 26.9% and
69.0%, respectively (Table 4).
DISCUSSION
This report presents the first clinical experience with
tacrolimus ointment for AD treatment in Taiwan. Our
results show that tacrolimus is effective and safe for
the treatment of moderate to severe AD in both
pediatric and adult patients. Tacrolimus produced
substantial clinical improvement rapidly, with about
70% of patients showing moderate improvement after
only 1 week of treatment. Quantitatively, the thera-
peutic efficacy of tacrolimus was demonstrated by
significant reductions in the percentage of BSA af-
fected and EASI. Subjectively, AD patients also appre-
ciated the improvement in the condition of their skin
by reporting a significant reduction in itch score with
the visual analog scale. Moreover, 88.5% of pediatric
patients and all adult patients reported a favorable
response to tacrolimus ointment.
Figure 4. (A) A 24-year-old man with erythematous, scaly
papuloplaques over the nuchal area during the baseline visit.
(B) After 1 week of treatment with topical tacrolimus ointment.
(C) After 4 weeks of treatment with topical tacrolimus ointment.
The previously affected site has improved significantly.
A
B
C
Figure 5. (A) A 5-year-old boy with excoriations and erythematous
papules over the popliteal fossa during the baseline visit. (B) After
1 week of treatment with topical tacrolimus ointment.
(C) Significant improvement is noted after 4 weeks of treatment.
A
B
C
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The adverse events and laboratory profiles docu-
mented during this study were consistent with those
of patients with an atopic diathesis [19–21]. Unlike
moderate and potent steroids, tacrolimus ointment
can be used safely on the face, neck, and intertriginous
areas. Detritus side effects, such as skin atrophy and
telangiectasia, associated with moderate and potent
topical steroids, were not reported in this study. The
most common adverse events reported in this study
were generally related to local irritation, such as a
burning sensation and stinging. This might be antici-
pated given the sensitive nature of atopic skin. These
events were temporary, occurred early on in treatment,
and were considered tolerable by most patients. Other
reported adverse events included folliculitis, fever,
and paresthesia. These side effects have also been
documented in similar studies conducted elsewhere
[12–16]. Skin paresthesia may reflect a local action of
tacrolimus on sensory nerves, which may also explain
its efficacy in reducing pruritus. Fever, although re-
ported by two patients in their journals, was not al-
ways confirmed by measuring body temperature.
These reports of fever could have been caused by
prolonged burning sensation on the skin. Folliculitis
was experienced by several patients, but the course
was mild and transient. The adverse events were tol-
erable and transient and did not result in discontinu-
ation of treatment.
During the study, there were no consistent changes
in any laboratory parameters that posed a safety
concern. The ELISA used did not detect any tacrolimus
in the blood samples examined. These results are con-
sistent with minimal absorption of tacrolimus through
affected skin.
In conclusion, our results indicate that the efficacy
and safety of tacrolimus ointment used to treat AD in
Taiwanese patients are comparable to those previ-
ously reported in Europe, the USA, and Japan [12–16].
Thus, tacrolimus ointment represents a safe and effec-
tive non-steroidal topical therapy for atopic patients
in Taiwan. Moreover, a high percentage of patients
included in this study had moderate or severe disease
and showed poor response to conventional therapy.
The high rate of treatment success demonstrated in
our study was, therefore, remarkable. However, this is
only the first clinical experience of topical tacrolimus
in Taiwan. More questions will be answered by further
studies. A long-term study is warranted to establish
the long-term safety and efficacy profiles of tacrolimus.
In addition, since tacrolimus ointment is available in
different concentrations (0.03% and 0.1%), further
study is required to establish therapeutic guidelines.
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